Skip to main content
SpringerLink
Log in

Cardiovascular Pathology in Acromegaly

  • Chapter
  • First Online:
Acromegaly

Part of the book series: Contemporary Endocrinology ((COE))

  • 247 Accesses

Abstract

Acromegaly patients have a two-fold higher mortality risk with high prevalence of hypertension and diabetes mellitus. Fortunately, this risk becomes comparable to the general population as growth hormone levels decrease <1 μg/L and normalization of insulin-like growth factor-1. Age of onset, disease duration, growth hormone levels, and hypertension are independent predictors of mortality. Surgery, radiation, and pharmacotherapy equally improve acromegaly induced cardiomyopathy by effectively controlling hormone hypersecretion, but somatostatin analogs have a unique ability to modify cardiac structure even when stringent criterion of disease control is not met through direct effect on cardiomyocyte proliferation and contractility. GH excess leads to concentric left ventricular hypertrophy and impaired diastolic filling with underlying interstitial fibrosis. Early detection and treatment are pivotal in ensuring reversibility of cardiac pathology before permanent changes develop. Once therapy is employed, cardiac remodeling happens rather quickly in a matter of months with effective lowering of GH/IGF-1. This brings home the most important message of early detection and starting effective therapy promptly, either it is surgery or pharmacotherapy when surgical cure is not possible or not achieved.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lombardi G, Galdiero M, Auriemma RS, Pivonello R, Colao A. Acromegaly and the cardiovascular system. Neuroendocrinology. 2006;83(3–4):211–7.

    Article  PubMed  CAS  Google Scholar 

  2. Fleseriu M. Insight into cardiovascular risk factors in patients with acromegaly. Endocrine. 2014;47(1):1–2.

    Article  PubMed  CAS  Google Scholar 

  3. Ramos-Levi AM, Marazuela M. Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management. Endocrine. 2017;55(2):346–59.

    Article  PubMed  CAS  Google Scholar 

  4. Gadelha MR, Kasuki L, Lim DST, Fleseriu M. Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev. 2019;40(1):268–332.

    Article  PubMed  Google Scholar 

  5. Akutsu H, Kreutzer J, Wasmeier G, Ropers D, Rost C, Mohlig M, et al. Acromegaly per se does not increase the risk for coronary artery disease. Eur J Endocrinol. 2010;162(5):879–86.

    Article  PubMed  CAS  Google Scholar 

  6. Ragonese M, Alibrandi A, Di Bella G, Salamone I, Puglisi S, Cotta OR, et al. Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction. Endocrine. 2014;47(1):206–12.

    PubMed  CAS  Google Scholar 

  7. Ioachimescu AG. Impact of acromegaly treatment on cardiovascular complications. Endocrine. 2017;55(3):659–61.

    Article  PubMed  CAS  Google Scholar 

  8. Guo X, Gao L, Zhang S, Li Y, Wu Y, Fang L, et al. Cardiovascular system changes and related risk factors in acromegaly patients: a case-control study. Int J Endocrinol. 2015;2015:573643.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Sharma AN, Tan M, Amsterdam EA, Singh GD. Acromegalic cardiomyopathy: epidemiology, diagnosis, and management. Clin Cardiol. 2018;41(3):419–25.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Colao A, Baldelli R, Marzullo P, Ferretti E, Ferone D, Gargiulo P, et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab. 2000;85(1):193–9.

    PubMed  CAS  Google Scholar 

  11. Gouya H, Vignaux O, Le Roux P, Chanson P, Bertherat J, Bertagna X, et al. Rapidly reversible myocardial edema in patients with acromegaly: assessment with ultrafast T2 mapping in a single-breath-hold MRI sequence. AJR Am J Roentgenol. 2008;190(6):1576–82.

    Article  PubMed  Google Scholar 

  12. Bondanelli M, Ambrosio MR, degli Uberti EC. Pathogenesis and prevalence of hypertension in acromegaly. Pituitary. 2001;4(4):239–49.

    Article  PubMed  CAS  Google Scholar 

  13. Minniti G, Moroni C, Jaffrain-Rea ML, Bondanini F, Gulino A, Cassone R, et al. Prevalence of hypertension in acromegalic patients: clinical measurement versus 24-hour ambulatory blood pressure monitoring. Clin Endocrinol (Oxf). 1998;48(2):149–52.

    Article  PubMed  CAS  Google Scholar 

  14. Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG. Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore). 1994;73(5):233–40.

    Article  PubMed  CAS  Google Scholar 

  15. Schutte AE, Volpe M, Tocci G, Conti E. Revisiting the relationship between blood pressure and insulin-like growth factor-1. Hypertension. 2014;63(5):1070–7.

    Article  PubMed  CAS  Google Scholar 

  16. Kamenicky P, Viengchareun S, Blanchard A, Meduri G, Zizzari P, Imbert-Teboul M, et al. Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly. Endocrinology. 2008;149(7):3294–305.

    Article  PubMed  CAS  Google Scholar 

  17. Rizzoni D, Porteri E, Giustina A, De Ciuceis C, Sleiman I, Boari GE, et al. Acromegalic patients show the presence of hypertrophic remodeling of subcutaneous small resistance arteries. Hypertension. 2004;43(3):561–5.

    Article  PubMed  CAS  Google Scholar 

  18. Hansen TK, Moller J, Thomsen K, Frandsen E, Dall R, Jorgensen JO, et al. Effects of growth hormone on renal tubular handling of sodium in healthy humans. Am J Physiol Endocrinol Metab. 2001;281(6):E1326–32.

    Article  PubMed  CAS  Google Scholar 

  19. Davies DL, Beastall GH, Connell JM, Fraser R, McCruden D, Teasdale GM. Body composition, blood pressure and the renin-angiotensin system in acromegaly before and after treatment. J Hypertens Suppl. 1985;3(3):S413–5.

    PubMed  CAS  Google Scholar 

  20. Lin CJ, Mendonca BB, Lucon AM, Guazzelli IC, Nicolau W, Villares SM. Growth hormone receptor messenger ribonucleic acid in normal and pathologic human adrenocortical tissues—an analysis by quantitative polymerase chain reaction technique. J Clin Endocrinol Metab. 1997;82(8):2671–6.

    PubMed  CAS  Google Scholar 

  21. Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H, et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf). 2000;52(5):549–55.

    Article  PubMed  CAS  Google Scholar 

  22. Ikeda T, Terasawa H, Ishimura M, Ochi H, Ohtani I, Fujiyama K, et al. Correlation between blood pressure and plasma insulin in acromegaly. J Intern Med. 1993;234(1):61–3.

    Article  PubMed  CAS  Google Scholar 

  23. Bondanelli M, Ambrosio MR, Franceschetti P, Margutti A, Trasforini G, Degli Uberti EC. Diurnal rhythm of plasma catecholamines in acromegaly. J Clin Endocrinol Metab. 1999;84(7):2458–67.

    PubMed  CAS  Google Scholar 

  24. Elmasry A, Lindberg E, Hedner J, Janson C, Boman G. Obstructive sleep apnoea and urine catecholamines in hypertensive males: a population-based study. Eur Respir J. 2002;19(3):511–7.

    Article  PubMed  CAS  Google Scholar 

  25. Grunstein RR, Ho KY, Sullivan CE. Sleep apnea in acromegaly. Ann Intern Med. 1991;115(7):527–32.

    Article  PubMed  CAS  Google Scholar 

  26. Schofl C, Petroff D, Tonjes A, Grussendorf M, Droste M, Stalla G, et al. Incidence of myocardial infarction and stroke in acromegaly patients: results from the German Acromegaly Registry. Pituitary. 2017;20(6):635–42.

    Article  PubMed  Google Scholar 

  27. Bogazzi F, Battolla L, Spinelli C, Rossi G, Gavioli S, Di Bello V, et al. Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J Clin Endocrinol Metab. 2007;92(11):4271–7.

    Article  PubMed  CAS  Google Scholar 

  28. Flickinger JC, Nelson PB, Taylor FH, Robinson A. Incidence of cerebral infarction after radiotherapy for pituitary adenoma. Cancer. 1989;63(12):2404–8.

    Article  PubMed  CAS  Google Scholar 

  29. Sardella C, Cappellani D, Urbani C, Manetti L, Marconcini G, Tomisti L, et al. Disease activity and lifestyle influence comorbidities and cardiovascular events in patients with acromegaly. Eur J Endocrinol. 2016;175(5):443–53.

    Article  PubMed  CAS  Google Scholar 

  30. Unubol M, Eryilmaz U, Guney E, Ture M, Akgullu C. QT dispersion in patients with acromegaly. Endocrine. 2013;43(2):419–23.

    Article  PubMed  CAS  Google Scholar 

  31. Auriemma RS, Pivonello R, De Martino MC, Cudemo G, Grasso LF, Galdiero M, et al. Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias. Eur J Endocrinol. 2013;168(1):15–22.

    Article  PubMed  CAS  Google Scholar 

  32. Chemla D, Attal P, Maione L, Veyer AS, Mroue G, Baud D, et al. Impact of successful treatment of acromegaly on overnight heart rate variability and sleep apnea. J Clin Endocrinol Metab. 2014;99(8):2925–31.

    Article  PubMed  CAS  Google Scholar 

  33. Breitschaft A, Hu K, Darstein C, Ligueros-Saylan M, Jordaan P, Song D, et al. Effects of subcutaneous pasireotide on cardiac repolarization in healthy volunteers: a single-center, phase I, randomized, four-way crossover study. J Clin Pharmacol. 2014;54(1):75–86.

    Article  PubMed  CAS  Google Scholar 

  34. Pereira AM, van Thiel SW, Lindner JR, Roelfsema F, van der Wall EE, Morreau H, et al. Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab. 2004;89(1):71–5.

    Article  PubMed  CAS  Google Scholar 

  35. Costenaro F, Martin A, Horn RF, Czepielewski MA, Rodrigues TC. Role of ambulatory blood pressure monitoring in patients with acromegaly. J Hypertens. 2016;34(7):1357–63.

    Article  PubMed  CAS  Google Scholar 

  36. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte AM, et al. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. J Clin Endocrinol Metab. 2001;86(4):1551–7.

    PubMed  CAS  Google Scholar 

  37. dos Santos Silva CM, Gottlieb I, Volschan I, Kasuki L, Warszawski L, Balarini Lima GA, et al. Low frequency of cardiomyopathy using cardiac magnetic resonance imaging in an acromegaly contemporary cohort. J Clin Endocrinol Metab. 2015;100(12):4447–55.

    Article  PubMed  Google Scholar 

  38. Auriemma RS, Grasso LF, Galdiero M, Galderisi M, Pivonello C, Simeoli C, et al. Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. Endocrine. 2017;55(3):872–84.

    Article  PubMed  CAS  Google Scholar 

  39. Mercado M, Gonzalez B, Vargas G, Ramirez C, de los Monteros AL, Sosa E, et al. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J Clin Endocrinol Metab. 2014;99(12):4438–46.

    Article  PubMed  CAS  Google Scholar 

  40. Gonzalez B, Vargas G, de Los Monteros ALE, Mendoza V, Mercado M. Persistence of diabetes and hypertension after multimodal treatment of acromegaly. J Clin Endocrinol Metab. 2018;103(6):2369–75.

    Article  PubMed  Google Scholar 

  41. Carmichael JD, Broder MS, Cherepanov D, Chang E, Mamelak A, Said Q, et al. The association between biochemical control and cardiovascular risk factors in acromegaly. BMC Endocr Disord. 2017;17(1):15.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Jonas C, Maiter D, Alexopoulou O. Evolution of glucose tolerance after treatment of acromegaly: a study in 57 patients. Horm Metab Res. 2016;48(5):299–305.

    Article  PubMed  CAS  Google Scholar 

  43. Tolis G, Angelopoulos NG, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, et al. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. Neuroendocrinology. 2006;83(3–4):249–57.

    Article  PubMed  CAS  Google Scholar 

  44. Gerich JE. Role of somatostatin and its analogues in the pathogenesis and treatment of diabetes mellitus. Metabolism. 1990;39(9 Suppl 2):52–4.

    Article  PubMed  CAS  Google Scholar 

  45. Lehnert H, Beyer J, Weber P, Krause U, Schrezenmeir J. Treatment of severe reactive hypoglycemia with a somatostatin analogue (SMS 201-995). Arch Intern Med. 1990;150(11):2401–2.

    Article  PubMed  CAS  Google Scholar 

  46. Minniti G, Moroni C, Jaffrain-Rea ML, Esposito V, Santoro A, Affricano C, et al. Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients. Clin Endocrinol (Oxf). 2001;55(3):307–13.

    Article  PubMed  CAS  Google Scholar 

  47. Colao A, Pivonello R, Galderisi M, Cappabianca P, Auriemma RS, Galdiero M, et al. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab. 2008;93(7):2639–46.

    Article  PubMed  CAS  Google Scholar 

  48. Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab. 2000;85(9):3132–40.

    PubMed  CAS  Google Scholar 

  49. Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2007;92(5):1743–7.

    Article  PubMed  CAS  Google Scholar 

  50. Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab. 2009;94(10):3746–56.

    Article  PubMed  CAS  Google Scholar 

  51. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab. 2001;86(6):2779–86.

    PubMed  CAS  Google Scholar 

  52. Giordano C, Ciresi A, Amato MC, Pivonello R, Auriemma RS, Grasso LF, et al. Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. Pituitary. 2012;15(4):539–51.

    Article  PubMed  CAS  Google Scholar 

  53. Colao A. 5 Long-term acromegaly and associated cardiovascular complications: a case-based review. Best Pract Res Clin Endocrinol Metab. 2009;23(Suppl 1):S31–8.

    Article  PubMed  Google Scholar 

  54. Colao A, Marzullo P, Cuocolo A, Spinelli L, Pivonello R, Bonaduce D, et al. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol (Oxf). 2003;58(2):169–76.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates

    Adnan Ajmal

Authors
  1. Adnan Ajmal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adnan Ajmal .

Editor information

Editors and Affiliations

  1. Department of Neurological Surgery, University of San Francisco, San Francisco, CA, USA

    Lewis S. Blevins Jr.

  2. Department of Neurological Surgery, University of San Francisco, San Francisco, CA, USA

    Manish K. Aghi

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ajmal, A. (2022). Cardiovascular Pathology in Acromegaly. In: Blevins Jr., L.S., Aghi, M.K. (eds) Acromegaly. Contemporary Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-031-16258-9_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-16258-9_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-16257-2

  • Online ISBN: 978-3-031-16258-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation